Bristol-Myers Squibb (NYSE:BMY) has returned the rights to a preclinical cancer drug candidate, an SOS1 inhibitor, back to Schrodinger (NASDAQ:SDGR). Schrodinger noted that it delivered a development...
Source LinkBristol-Myers Squibb (NYSE:BMY) has returned the rights to a preclinical cancer drug candidate, an SOS1 inhibitor, back to Schrodinger (NASDAQ:SDGR). Schrodinger noted that it delivered a development...
Source Link
Comments